Can we really lessen kidney damage to the point that the loss of renal function of progressive nephropathy may revert?

Journal of the American Society of Nephrology

Volumn 14, Issue 5, 2003, Pages 1411-1414

  Abbate, Mauro ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HYDRALAZINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

DIET THERAPY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0037408534     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000067478.61759.42     Document Type: Editorial

References (29)

1. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001
2. Brenner BM: Remission of renal disease: Recounting the challenge, acquiring the goal. J Clin Invest 110: 1753-1758, 2002
3. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G: ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 34: 626-632, 1999
4. Meyer TW, Anderson SA, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31: 752-759, 1987
5. Beukers JJB, van der Wal A, Hoedemaeker PJ, Weening JJ: Converting enzyme inhibition and progressive glomerulosclerosis in the rat. Kidney Int 32: 794-800, 1987
6. Inserra F, Romano LA, De Cavanagh E, Ercole L, Ferder LF, Gomez RA: Renal interstitial sclerosis in aging: Effects of enalapril and nifedipine. J Am Soc Nephrol 7: 676-680, 1996
7. Ruiz-Torres MP, Bosch RJ, O'Valle F, Del Moral RG, Ramirez C, Masseroli M, Perez-Caballero C, Iglesias MC, Rodriguez-Puyol M, Rodriguez-Puyol D: Age-related increases in expression of TGF-β1 in the rat kidney: Relationship to morphologic changes. J Am Soc Nephrol 9: 782-791, 1998
8. Verseput GH, Provoost AP, Braam BB, Weening JJ, Koomans HA: Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive Fawn-Hooded rat. J Am Soc Nephrol 8: 249-259, 1997
9. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40: 195-202, 1991
10. Ma L-J, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 58: 2425-2436, 2000
11. Remuzzi A, Gagliardini E, Donadoni A, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 62: 885-894, 2002
12. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13: 2898-2908, 2002
13. Boffa J-J, Lu Y, Placier S, Stefanski A, Dussaule J-C, Chatziantoniou C: Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Neprhol 14: 1132-1144, 2003
14. Ziyadeh FN, Hoffman BB, Cheol Han D, Iglesias-de la Cruz MC, Won Hong S, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-β antibody in db/db diabetic mice. PNAS 97: 8015-8020, 2000
15. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. JCI 110: 1525-1538, 2002
16. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Hoon Choi J, Troy JL, Brenner BM: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12: 2051-2059, 2001
17. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61: 1635-1645, 2002
18. Remuzzi G, Zoja C, Gagliardini E, Coma D, Abbate M, Benigni A: Combining an antiproteinuric approach with micophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549, 1999
19. Nangaku M, Pippin J, Couser WG: C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 13: 928-936, 2002
20. Muller DN, Shagdarsuren E, Park J-K, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC: Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693, 2002
21. The GISEN Group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
22. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G, on behalf of Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352: 1252-1256, 1998
23. Parving H-H, Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen F, Gall MA: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 22: 188, 1993
24. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 10: 997-1006, 1999
25. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP: Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 34: 308-314, 1999
26. Breyer Lewis J, Berl T, Bain RP, Rohde RD, Lewis EJ, and the Collaborative Study Group: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 34: 809-817, 1999
27. Ruggenenti P, Brenner BM, Remuzzi G: Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 88: 254-259, 2001
28. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
29. Trivedi HS, Pang MMH, Campbell A, Saab P: Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 39: 721-729, 2002